Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective

Published:2022-10 Issue: Volume:184 Page:106426
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Yadav Poonam,Khurana Amit,Bhatti Jasvinder Singh,Weiskirchen Ralf,Navik Umashanker

Funder

University Grants Commission

China University of Petroleum, Beijing

University of Central Punjab

Indian Council of Medical Research

Publisher

Elsevier BV

Subject

Pharmacology

Reference119 articles.

1. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis;Pydyn;Pharm. Rep.,2020

2. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study;Williams;Gastroenterology,2011

3. From NAFLD to MAFLD: nurse and allied health perspective;Clayton;Liver Int.,2021

4. L-Methionine supplementation attenuates high-fat fructose diet-induced non-alcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats;Navik;Food Funct.,2022

5. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement;Eslam;J. Hepatol.,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family;Military Medical Research;2024-06-21

2. Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis;The Journal of Clinical Endocrinology & Metabolism;2024-05-02

3. Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challenges;Pharmacology & Therapeutics;2024-01

4. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD;Current Pharmaceutical Design;2024-01

5. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists;Obesity Reviews;2023-11-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3